Pressrelease

Uppsala 17th December 2018

Nanexa signs agreement with pharmaceutical company for evaluation of PharmaShell®

A Swedish listed pharmaceutical company begins evaluating Nanexa’s drug delivery platform PharmaShell® as a possible technology to use in a specific product development project. The evaluation that is regulated by a “Material Transfer and Feasibility study agreement” will start shortly.

The evaluation work begins with an in vitro study which is planned to be followed, in a second step, with an in vivo study. The work will form the basis for negotiating an extended commercial agreement regarding PharmaShell®.

In the now agreed collaboration, Nanexa receives agreed smaller payments on signing, delivery of in vitro results and on delivery of materials for an in vivo study. The Swedish pharmaceutical company with which Nanexa has signed an agreement also pays for the in vivo study planned within the framework of the evaluation.

 

Nanexa’s CEO David Westberg comments:

The work we systematically put into developing and marketing PharmaShell® is now starting to pay off. This time it is a Swedish pharmaceutical company that has chosen to evaluate PharmaShell® for a specific product development project. Of course, this is extremely gratifying and we look forward to working with another company that wants to evaluate our technology platform.

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.